Oxford BioMedica and Sanofi Amend Terms for Ocular Licence
— Oxford BioMedica regains worldwide rights to EncorStat® — — Sanofi broadens global rights to StarGen™ and UshStat® across all disease indications –… Read More
Publication of ProSavin® Phase I/II Study in The Lancet
Oxford BioMedica Announces Publication of ProSavin® Phase I/II Study in The Lancet — Pioneering data published in world-leading, peer-reviewed medical journal —… Read More
Oxford BioMedica to present at Biotech Showcase
Oxford, UK – 9 January 2014: Oxford BioMedica plc (“Oxford BioMedica” or “the Company”) (LSE:OXB), the leading gene-based biopharmaceutical company, announces that John Dawson, Chief Executive Officer, will present a company overview at the Biotech Showcase… Read More
Results of General Meeting
Oxford, UK – 6 January 2014: Oxford BioMedica plc (“Oxford BioMedica” or “the Company”) (LSE:OXB), the leading gene-based biopharmaceutical company, announced the results of its General Meeting held today in London. In accordance with Listing Rule 9.6.18, the… Read More
Option Agreement with GlaxoSmithKline
Oxford, UK – 18 December 2013: Oxford BioMedica plc (“Oxford BioMedica” or “the Company”) (LSE:OXB), the leading gene-based biopharmaceutical company, announces that it has signed an option agreement with GlaxoSmithKline (“GSK”) which grants GSK an option to a… Read More
Oxford, UK – 18 December 2013: Oxford BioMedica plc (“Oxford BioMedica” or “the Company”) (LSE:OXB), the leading gene-based biopharmaceutical company, announces that it has signed an option agreement with GlaxoSmithKline (“GSK”) which grants GSK an optio
Oxford, UK – 19 November 2013: Oxford BioMedica (“Oxford BioMedica” or “the Company”) (LSE:OXB), the leading gene-based biopharmaceutical company, today announces that it has signed a £5 million secured loan facility agreement with its largest shareholder, the Vulpes… Read More
Interim Management Statement
Oxford, UK – 19 November 2013: Oxford BioMedica (“Oxford BioMedica” or “the Company”) (LSE:OXB), the leading gene-based biopharmaceutical company, today publishes its interim management statement for the period from 1 July to 18 November 2013. … Read More
Oxford BioMedica Receives Agreement from FDA and ANSM to Resume Recruitment into Ocular Clinical Trials
— Newly developed, state-of-the-art analytical methods confirm the integrity and quality of Oxford BioMedica’s LentiVector® platform products — Oxford, UK – 17 October 2013: Oxford BioMedica plc (“Oxford BioMedica” or “the… Read More
Oxford BioMedica Wins Significant Funding via a Competitive Award from UK Government’s Advanced Manufacturing Supply Chain Initiative
— UK consortium wins £7.7 million total funding, of which £7.1 million awarded to Oxford BioMedica as lead member —… Read More
Oxford BioMedica plc Interim Results for the Six Months Ended 30 June 2013
Click here to download the full 2013 interim results statement.Click here to download the 2013 interim results presentation. Read More
Oxford BioMedica Announces US$1 million Milestone Payment from Pfizer
— Phase I clinical trial for 5T4-targeted antibody therapy underway — Oxford, UK – 28 August 2013: Oxford BioMedica (“Oxford BioMedica” or “the… Read More
Oxford BioMedica Announced as Regenerative Medicine and Cell Therapy Funding Competition Winner by the UK’s innovation agency, the Technology Strategy Board
— Funding to be received for the development of a novel therapeutic treatment to engineer corneas to resist graft rejection — Oxford,… Read More